Egetis Therapeutics

Egetis Therapeutics is an innovative pharmaceutical company specializing in the development and commercialization of treatments for serious diseases with significant unmet medical needs, particularly in the orphan drug segment. The company's lead drug candidate, Emcitate® (tiratricol), is developed for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a rare and debilitating condition. Egetis is also exploring the potential of Emcitate for resistance to thyroid hormone beta (RTHβ), another rare disorder. The company operates primarily in late-stage drug development, aiming to bring novel therapies to market for conditions with no existing treatments.

40

1.05

1.01

— Egetis Therapeutics
%
Orphan Drugs80% Includes drugs for rare diseases with significant unmet needs.
Clinical Trials15% Conducting trials for drug efficacy and safety.
Regulatory Approvals5% Securing approvals for drug commercialization.

Egetis Therapeutics primarily serves healthcare providers and patients affected by rare diseases, particularly those...

  • Healthcare Providersprimary

    Purchase Emcitate for treating rare diseases.

  • Academic Research Groupssecondary

    Collaborate on studies for new indications.

  • Patients and Familiesemerging

    Seek treatments for rare and debilitating conditions.

Egetis Therapeutics is based in Sweden and operates primarily within the European Union, where it recently received...

  • •Headquartered in Sweden
  • •EU approval for Emcitate for MCT8 deficiency
  • •Planned launch in Germany in 2025
  • •Clinical trials conducted in the US
  • •Global reach for orphan drug markets

Egetis Therapeutics focuses on advancing its lead candidate, Emcitate, through regulatory approvals and market...

01
Regulatory Approvalsshort-term

To commercialize Emcitate in the EU and US.

02
Indication Expansionmedium-term

To increase Emcitate's market potential.

03
Market Launchmedium-term

To establish a presence in key markets.

Egetis Therapeutics faces several risks, including the inherent uncertainties of pharmaceutical development and...

critical

Regulatory Approval Delays

Could delay market entry and revenue generation.

Materiality
high
critical

Clinical Trial Outcomes

Negative results could halt development.

Materiality
high
high

Geopolitical Instability

May disrupt R&D activities.

Materiality
medium
Revenue Recognition
Income Statement Transition

PTC THERAPEUTICS, INC.

PTCT · Pharmaceutical Preparations

Edgewise Therapeutics, Inc.

EWTX · Pharmaceutical Preparations

BICYCLE THERAPEUTICS PLC

BCYC · Pharmaceutical Preparations

Akebia Therapeutics, Inc.

AKBA · Pharmaceutical Preparations

AGIOS PHARMACEUTICALS, INC.

AGIO · Pharmaceutical Preparations

AMICUS THERAPEUTICS, INC.

Pharmaceutical Preparations

: 11/08/2026